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Abstract: Our purpose was to investigate the effect of different zinc metabolic disorders on alkaline phosphatase activity. Serum
zinc, glucose and alkaline phosphatase activity were studied in 32 patients with liver cirrhosis, 30 with chronic renal failure and 42
with insulin-dependent diabetes mellitus (IDDM) compared to 42 healthy volunteers. Serum glucose concentration was significantly
higher (P < 0.001) in IDDM and liver cirrhosis patients (P < 0.05) compared to the controls. Serum zinc concentrations tended to
be lower in all different diseases but did not reach statistical significance. Alkaline phosphatase activity was higher in IDDM (P <
0.05) and liver cirrhosis patients (P < 0.01) compared with the controls. No positive correlation between serum zinc and alkaline
phosphatase activity was recorded in any disease. In conclusion, the investigated diseases did not affect the level of serum zinc;
however, there was an alteration in alkaline phosphatase activity in patients suffering from diabetes and liver cirrhosis. Consequently,
this may be attributed to the functional disturbance that occurred in these patients. Finally, zinc concentration did not follow alkaline
phosphatase activity as indicated by the weak correlation obtained.
Key Words: Zinc, liver cirrhosis, diabetes, chronic renal failure, alkaline phosphatase

Introduction
Zinc is recognised as essential for the activity of a
wide range of enzymes, and the first demonstration that
zinc had a special biological function in relation to enzyme
function came with the discovery that carbonic anhydrase
contained significant amount of zinc which appeared to be
required for normal activity (1). Zinc participates in either
the activation of enzyme systems forming a metalloenzyme complex or non-specifically as a constituent of
enzyme forming metallo-enzymes including lactic
dehydrogenase, malate dehydrogenase, RNA polymerase,
sorbitol dehydrogenase, alkaline phosphatase, and
angiotensin I (2-6). A reduction in tissue zinc
concentrations may lead to a reduction in the activity of a
wide range of enzymes, which are dependent on this
element for normal function. Carbonic anhydrase and

alcohol dehydrogenase are two examples of enzymes that
are particularly sensitive to reductions in tissue zinc
concentration (7,8) Zinc deficiency in humans may result
from inadequate dietary zinc intake, especially during
pregnancy (9), lactation (10) and periods of rapid growth
when requirements are high, or as a result of other
factors which affect zinc availability. Zinc depletion in
humans may also occur as a result of unusual
circumstances, which result in increased zinc loss from
the body. These include excessive sweating (11), chronic
blood loss, the development of disease states such as
diabetes (12,13), liver cirrhosis (14,15), chronic renal
failure (16) and gastrointestinal disorders (17), and heart
failure (18). On the basis of all this previous informations,
the present study was undertaken to investigate the
effect of these diseases on alkaline phosphatase activity in
humans.
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Materials and Methods
The experimental protocol consists of:
Patients
Thirty-two adults (18 men and 14 women) with liver
cirrhosis, with a mean age of
51.4 ± 6.1 years (range 24-61 years). No patient had
any other diseases which might influence the results.
Thirty patients (17 men and 13 women) with chronic
renal failure and a mean age of
27 ± 4.1 years (range 22-60 years).
Forty-two subjects (20 men and 22 women) with
type I diabetes mellitus (IDDM). The subjects ranged in
age from 25 to 45 years (mean age 32.5 ± 4.6 years).
Controls
Healthy volunteers (biology students and members of
the staff were used as controls
(22 men and 20 women) with an average age of 24
± 7.3 (range 20-52 years).
Methods
Venous blood was collected in the morning at 8.00
after an overnight fast from patients and controls for
measurements of whole blood glucose, serum zinc, and
alkaline phosphatase activity.

Statistical Analysis
The results are given as the mean and standard error
of the mean. Comparisons between groups are assessed
using Student’s t-test. The data were also analysed for
correlations between the serum zinc and alkaline
phosphatase activity in all diseases.
(The number of samples used in this statistical analysis
was 15 from each disease). The results were considered
significant when P < 0.05.

Results
Glucose concentrations were significantly higher in
IDDM (P < 0.001) and liver cirrhosis patients (P < 0.05)
compared to the control group. Serum zinc
concentrations in all different diseases were lower than
those in the control group, but were not significant.
Serum alkaline phosphatase activity was higher in IDDM
(P < 0.05) and liver cirrhosis patients (P < 0.01)
compared with the controls (Table). The data were
analysed to see if any correlation could be found between
serum zinc and alkaline phosphatase activity in all
diseases: diabetes (r = 0.252), liver cirrhosis (r = 0.387),
and chronic renal failure (r = 0.266). According to the
results reported in the Figure, a negative correlation
between serum zinc and alkaline phosphatase activity was
established.

Analysis
Zinc concentration was measured in duplicate after
20-fold dilution of serum in double distilled water by
flame atomic absorption spectrophotometer (Pye Unicam
SP 9000) at 213.8 nm. Zinc standards were prepared
from a 1 mg/ml zinc nitrate standard solution (BDH)
using 5% glycerol to approximate the viscosity
characteristics, and to avoid zinc contamination from
exogenous sources. All tubes were soaked in HCl (10%
v/v) for 16 h and rinsed with double distilled water (19).
Blood glucose was measured in 10 ml samples of
fresh whole blood by the glucose oxidase (EC 1.1. 3. 4)
method, using a YSI Model 27 glucose analyser and a kit
comprising phosphate buffer containing the enzymes
(GOD, POD) and D-glucose (Sigma).
Alkaline phosphatase activity was determined using
commercial test kits comprising 1 mol/l diethanolamine
HCl buffer pH 9.8, 0.5 mmol/l magnesium chloride and
10 mmol/l of the substrate p-nitrophenylphosphate (20).
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Discussion
Zinc is essential for the activity of more than 100
enzymes that participate in the major metabolic
pathways. Over 40 metallo-enzymes exist in which zinc is
bound to the apoenzyme in specific stoichiometric ratios,
where it serves as one or more structural, regulatory or
catalytic functions (1). A number of studies have indicated
that changes in the concentration of zinc in tissues and
body fluids follow the course of some diseases such as
diabetes, liver cirrhosis, chronic renal failure and gastrointestinal disorders, according to the relationships
between zinc and alkaline phosphatase and the effect of
the diseases mentioned above. The present investigation
reveals the net effect of these diseases on alkaline
phosphatase activity. In this experiment, serum glucose
concentrations in patients with IDDM are much higher
than those of the controls. This confirms the diabetic
state. Serum glucose concentrations of liver cirrhosis
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Table. Glucose (mg/100ml), serum zinc (µg/100 ml) and alkaline phosphatase activity (UI/l)in patients with liver cirrhosis,
diabetes mellitus (IDDM) type I, chronic renal failure and controls.
Glucose concentration

Serum Zinc

Alkaline phosphatase

Mean ± SE

Mean ± SE

Mean ± SE

Sample

Control group

(n = 42)

80

8

81

3.7

79

4

Liver cirrhosis

(n = 32)

132*

10

61

14

152**

10

Diabetes mellitus

(n = 42)

284***

14

77

2.4

117*

14

88

15

68

12

87

8

Chronic renal failure (n = 30)

* (P < 0.05); ** (P < 0.01); *** (P < 0.001): Significantly different from control;
n: number of samples.

y = -0 .1999 x + 83 .624
R = 0.252

Zinc concentration
µg per 100 ml

100

Diabetes mellitus(n=15)

80
60
40
20
0
0

50
100
Alkaline phosphatase activity UI/l
y = 0 . 2628 x + 27 . 081

100

R = 0 . 387

Zinc concentration
µg per 100 ml

120

150

Liver cirrhosis (n=15)

80
60
40
20
0
0

50

100

150

200

Alkaline phosphatase activity UI/l
y = 0 .1889 x + 42 .55

100

Chronic renal failure (n=15)

Zinc concentration
µg per 100 ml

R = 0 .266
80
60
40
20
0
0

20

40
60
80
Alkaline phosphatase activity UI/l

100

120

Figure. Showing the correlation between serum zinc and alkaline phosphatase activity in
liver cirrhosis, diabetes mellitus (IDDM) and chronic renal failure, n is the number
of samples (The number of samples used in this correlation was 15 from each
disease).
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patients were also higher than those of healthy people;
this is likely related to liver dysfunction (21,22). There
are non-significant differences in serum zinc
concentrations between patients with all the different
diseases and the control group. This result clearly
demonstrated the ability of these patients to reduce zinc
losses from the body. For example, they may have had
decreased endogenous zinc secretion into the gastrointestinal tract (23,24) or increased efficiency of
absorption of zinc from their diet (25,26), or the patients
had a high efficiency to retain zinc in their bodies (27). In
our study, there was a significant rise in serum alkaline
phosphatase activity in patients with IDDM and liver
cirrhosis compared with the controls. The results are in
total agreement with some previously published reports
(2,28,29). The increase in serum alkaline activity in the
diabetic state could be as a result of an increased call for
energy through alkaline phosphatase activity rather than
the glycolytic and oxidative pathway of glucose 6
phosphate, and in cirrhosis disease it might be attributed
to the cytolysis and leakage out of necrotic or damaged
cells in the liver. In addition, the statistical evaluation
showed there was not a good correlation between serum
zinc concentration and alkaline phosphatase activity.

In conclusion, these different diseases did not affect
the level of serum zinc. There was also an alteration in
alkaline phosphatase activity in patients with diabetes and
liver cirrhosis. This may be due to the pathological
changes which occurred in these diseases. However, there
was in general no positive correlation between serum zinc
and alkaline phophatase activity.
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